KO-Validated Antibodies
Knockout (KO) validation offers the most rigorous proof of antibody specificity. Every antibody in this collection is verified against CRISPR/Cas9 or genetic knockout cell models, showing complete signal loss in target-null lysates to rule out cross-reactivity across cell biology, oncology and metabolic signaling research.
Browse KO-Validated AntibodiesTwo Targets Confirmed by Direct Knockout Comparison
AIFM1 and AKT1 are two of the more heavily requested targets in the range, each backed by a published wild-type versus knockout comparison rather than a single positive-control image. AIFM1 sits at the centre of mitochondrial apoptosis signaling, while AKT1 anchors the PI3K/AKT pathway studied across proliferation and survival research.
Anti-AIFM1 Antibody (334-613) (STJ22557)
AIFM1 (apoptosis-inducing factor 1) is a mitochondrial flavoprotein that translocates to the nucleus during caspase-independent cell death. This rabbit polyclonal antibody is confirmed by knockout validation in confocal immunofluorescence of HeLa cells, supporting WB, IHC-P, IF/ICC and ELISA in human, mouse and rat samples.
View product →
Anti-AKT1 Antibody (380-480) [S4954RM] (STJ11104954)
AKT1 is a serine/threonine kinase downstream of PI3K, studied for its role in cell survival and proliferation signaling. This rabbit monoclonal antibody is validated by confocal imaging of MCF7 cells against knockout controls, and supports WB, IHC-P, IF/ICC and ELISA in human, mouse and rat samples.
View product →How Our Knockout Validated Antibodies Are Tested and Used
Antibody cross-reactivity is a recognised driver of irreproducibility in life science research.1,2 KO validation uses CRISPR/Cas9 or genetic ablation to remove expression of the target protein. Comparing antibody binding between wild-type (WT) and knockout (KO) cell lysates confirms that target-specific detection is lost in the KO control. Our range currently lists over 700 KO-validated primary antibodies, spanning monoclonal and polyclonal formats across mouse and rabbit hosts.
What makes knockout (KO) validation the gold standard in antibody testing?
Unlike peptide competition or positive cell controls, KO validation removes the target gene entirely. Signal loss in the KO lane provides direct confirmation that the antibody does not cross-react with non-target proteins.1
Which applications are supported in the KO-validated range?
Products in this range are tested and confirmed for Western Blotting (WB), Immunohistochemistry (IHC-P), Flow Cytometry (FC), Immunofluorescence (IF/ICC), Immunoprecipitation (IP) and ELISA, depending on the individual product.
How does KO validation benefit research on related protein families?
For protein families with related isoforms, such as the annexin or Rho GTPase families, KO testing confirms the antibody detects the specific target without cross-binding to close relatives.2
KO-Validated Antibodies for Cell Biology
AES, ANKRD52, ARF5 and ANXA6 cover transcriptional repression, phosphatase regulation, vesicle trafficking and membrane-associated calcium binding. AES is a Groucho/TLE-family corepressor recruited by transcription factors to silence target genes. ANKRD52 is a regulatory subunit of the PP6 phosphatase complex. ARF5 is a small GTPase in the ADP-ribosylation factor family that coordinates Golgi and vesicle trafficking. ANXA6 is a calcium and phospholipid-binding annexin implicated in membrane organisation. Each antibody below is confirmed against a wild-type versus knockout lysate comparison.
KO-Validated Antibodies for Cancer Research
AKT1, ANXA1 and ARHGEF1 sit within pathways studied for their roles in tumour cell signaling and invasion. AKT1 is a core effector of PI3K signaling linked to cell survival and proliferation. ANXA1 is a glucocorticoid-regulated protein studied in inflammation resolution and tumour biology. ARHGEF1 is a Rho guanine nucleotide exchange factor implicated in cytoskeletal signaling relevant to cell migration. Each antibody below carries a direct wild-type versus knockout comparison.
KO-Validated Antibodies for Metabolic & Cell Signaling
AKR1A1, ALDH3A2, AIFM1 and APP span carbonyl detoxification, fatty aldehyde metabolism, mitochondrial redox biology and regulated proteolytic signaling. AKR1A1 reduces a wide range of aldehydes and ketones as part of cellular detoxification.3 ALDH3A2 metabolises fatty aldehydes generated during lipid turnover. AIFM1 is a mitochondrial flavoprotein with roles in oxidative phosphorylation and apoptosis signaling. APP undergoes regulated proteolysis to release fragments studied in cell signaling contexts. Knockout validation confirms specific detection for each target.
Looking for a Specific KO-Validated Target?
Explore our full catalogue of knockout-validated primary antibodies or contact our scientific team for technical data sheets and validation support.
Browse KO-Validated Antibodies1. Uhlen M, et al. A proposal for validation of antibodies. Nat Methods. 2016;13(11):923-927.
2. Bordeaux J, et al. Guidelines for antibody verification in scientific research. Biotechniques. 2010;48(3):197-209.
3. UniProt Knowledgebase, entry P14550 (AK1A1_HUMAN), accessed 2026.